Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Standard of Care Treatment (Hormonal Therapy and Stereotactic Ablative Radiation Therapy) Alone or in Combination with Niraparib, Abiraterone and Prednisone for the Treatment of Metastatic Prostate Cancer, KNIGHTS Trial

Trial Status: active

This phase II trial compares the effectiveness of standard of care treatment, hormonal therapy and ablative radiation therapy (SABR), to standard of care treatment in combination with niraparib, abiraterone and prednisone in treating patients with prostate cancer that has spread from where it first started to other places in the body (metastatic). Hormonal therapy, such as leuprolide, goserelin, buserelin, histrelin, triptorelin, degarelix, or relugolix, may lower the amount of testosterone made by the body or block the use of testosterone by the tumor cells. This may help stop the growth of tumor cells that need testosterone to grow. SABR is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Niraparib is in a class of medications called poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Abiraterone acetate, an androgen biosynthesis inhibitor, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Standard of care treatment in combination with niraparib, abiraterone acetate and prednisone may be more effective than standard of care alone in treating patients with metastatic prostate cancer.